Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 164

1.

Early improvement of glycaemic control after virus clearance in patients with chronic hepatitis C and severe liver fibrosis: a cohort study.

Lanini S, Bartolini B, Taibi C, Agresta A, Garbuglia AR, Montaldo C, Pisapia R, D'Offizi G, Scognamiglio P, Capobianchi MR, Zumla A, Ippolito G.

New Microbiol. 2019 Jul 15;42(2). [Epub ahead of print]

2.

Liver sinusoidal endothelial cells (LSECs) modifications in patients with chronic hepatitis C.

Baiocchini A, Nonno FD, Taibi C, Visco-Comandini U, D'Offizi G, Piacentini M, Falasca L.

Sci Rep. 2019 Jun 19;9(1):8760. doi: 10.1038/s41598-019-45114-1.

3.

Daclatasvir, sofosbuvir with or without ribavirin for 24 weeks in hepatitis C genotype 3 cirrhosis: A real-life study.

Lionetti R, Piccolo P, Lenci I, Siciliano M, Visco-Comandini U, De Santis A, Pompili M, Milana M, Taibi C, Dell'Isola S, Montalbano M, Mastroianni C, Begini P, Garbuglia AR, Angelico M, D'Offizi G.

Ann Hepatol. 2019 May - Jun;18(3):434-438. doi: 10.1016/j.aohep.2018.09.005. Epub 2019 Apr 15.

4.

Daclatasvir-based regimens in HCV cirrhosis: experience from the Italian early access program.

Calvaruso V, Mazzarelli C, Milazzo L, Badia L, Pasulo L, Guaraldi G, Lionetti R, Villa E, Borghi V, Carrai P, Alberti A, Biolato M, Piai G, Persico M, Santantonio T, Felder M, Angelico M, Montalbano M, Mancusi RL, Grieco A, Angeli E, D'Offizi G, Fagiuoli S, Belli L, Verucchi G, Puoti M, Craxì A.

Sci Rep. 2019 Jan 24;9(1):585. doi: 10.1038/s41598-018-36734-0.

5.

Extended infusion of β-lactams for bloodstream infection in patients with liver cirrhosis: an observational multicenter study.

Bartoletti M, Giannella M, Lewis RE, Caraceni P, Tedeschi S, Paul M, Schramm C, Bruns T, Merli M, Cobos-Trigueros N, Seminari E, Retamar P, Muñoz P, Tumbarello M, Burra P, Cerenzia MT, Barsic B, Calbo E, Maraolo AE, Petrosillo N, Galan-Ladero MA, D'Offizi G, Zak-Doron Y, Rodriguez-Baño J, Baldassarre M, Verucchi G, Domenicali M, Bernardi M, Viale P; ESGBIS/BICHROME study group.

Clin Infect Dis. 2019 Jan 14. doi: 10.1093/cid/ciz032. [Epub ahead of print]

PMID:
30649218
6.

Clinical and virological properties of hepatitis C virus genotype 4 infection in patients treated with different direct-acting antiviral agents.

Minosse C, Selleri M, Giombini E, Bartolini B, Capobianchi MR, Cerilli S, Loiacono L, Taibi C, D'Offizi G, McPhee F, Garbuglia A.

Infect Drug Resist. 2018 Nov 2;11:2117-2127. doi: 10.2147/IDR.S179158. eCollection 2018.

7.

Lack of reduction in serum alpha-fetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with hepatitis C virus-related cirrhosis.

Masetti C, Lionetti R, Lupo M, Siciliano M, Giannelli V, Ponziani FR, Teti E, Dell'Unto C, Francioso S, Brega A, Montalbano M, Visco-Comandini U, Taibi C, Galati G, Vespasiani Gentilucci U, Picardi A, Andreoni M, Pompili M, Pellicelli AM, D'Offizi G, Gasbarrini A, De Santis A, Angelico M.

J Viral Hepat. 2018 Dec;25(12):1493-1500. doi: 10.1111/jvh.12982. Epub 2018 Sep 6.

PMID:
30112854
8.

Effectiveness and safety of simeprevir-based regimens for hepatitis C in Italy: The STIly observational study.

Gaeta GB, Aghemo A, Menzaghi B, D'Offizi G, Giorgini A, Hasson H, Brancaccio G, Palma M, Termini R; STIly Study Group.

Medicine (Baltimore). 2018 Jul;97(27):e11307. doi: 10.1097/MD.0000000000011307.

9.

Long-Term Follow-Up of Acute Hepatitis B: New Insights in Its Natural History and Implications for Antiviral Treatment.

Menzo S, Minosse C, Vincenti D, Vincenzi L, Iacomi F, Zaccaro P, D'Offizi G, Capobianchi MR.

Genes (Basel). 2018 Jun 12;9(6). pii: E293. doi: 10.3390/genes9060293.

10.

Impact of new DAA therapy on real clinical practice: a multicenter region-wide cohort study.

Lanini S, Scognamiglio P, Mecozzi A, Lombardozzi L, Vullo V, Angelico M, Gasbarrini A, Taliani G, Attili AF, Perno CF, De Santis A, Puro V, Cerqua F, D'Offizi G, Pellicelli A, Armignacco O, Mennini FS, Siciliano M, Girardi E, Panella V, Ippolito G; members of the Lazio Region HCV treatment group.

BMC Infect Dis. 2018 May 16;18(1):223. doi: 10.1186/s12879-018-3125-6.

11.

Significance of detectable HCV RNA below the limit of quantification in patients treated with DAAs using standard and ultrasensitive protocols.

Visco-Comandini U, Lapa D, Lionetti R, Taibi C, Loiacono L, Montalbano M, Capobianchi MR, D'Offizi G, Garbuglia AR.

J Med Virol. 2018 Jul;90(7):1264-1271. doi: 10.1002/jmv.25084. Epub 2018 Apr 26.

PMID:
29611880
12.

Hepatitis C virus direct-acting antivirals therapy impacts on extracellular vesicles microRNAs content and on their immunomodulating properties.

Santangelo L, Bordoni V, Montaldo C, Cimini E, Zingoni A, Battistelli C, D'Offizi G, Capobianchi MR, Santoni A, Tripodi M, Agrati C.

Liver Int. 2018 Oct;38(10):1741-1750. doi: 10.1111/liv.13700. Epub 2018 Feb 24.

PMID:
29359389
13.

Trans-arterial radio-embolization: a new chance for patients with hepatocellular cancer to access liver transplantation, a world review.

Levi Sandri GB, Ettorre GM, Giannelli V, Colasanti M, Sciuto R, Pizzi G, Cianni R, D'Offizi G, Antonini M, Vennarecci G, Lucatelli P.

Transl Gastroenterol Hepatol. 2017 Nov 27;2:98. doi: 10.21037/tgh.2017.11.11. eCollection 2017. Review.

14.

Sofosbuvir plus daclatasvir with or without ribavirin is safe and effective for post-transplant hepatitis C recurrence and severe fibrosis and cirrhosis: A prospective study.

Lionetti R, Calvaruso V, Piccolo P, Mancusi RL, Mazzarelli C, Fagiuoli S, Montalbano M, Lenci I, Carrai P, Guaraldi G, Visco-Comandini U, Milana M, Biolato M, Loiacono L, Valente G, Craxì A, Angelico M, D'offizi G.

Clin Transplant. 2018 Feb;32(2). doi: 10.1111/ctr.13165. Epub 2017 Dec 18.

PMID:
29193356
15.

Intrahepatic Vγ9Vδ2 T-cells from HCV-infected patients show an exhausted phenotype but can inhibit HCV replication.

Cimini E, Bordoni V, Sacchi A, Visco-Comandini U, Montalbano M, Taibi C, Casetti R, Lalle E, D'Offizi G, Capobianchi MR, Agrati C.

Virus Res. 2018 Jan 2;243:31-35. doi: 10.1016/j.virusres.2017.10.008. Epub 2017 Oct 10.

PMID:
29029951
16.

A prospective multicentre study of the epidemiology and outcomes of bloodstream infection in cirrhotic patients.

Bartoletti M, Giannella M, Lewis R, Caraceni P, Tedeschi S, Paul M, Schramm C, Bruns T, Merli M, Cobos-Trigueros N, Seminari E, Retamar P, Muñoz P, Tumbarello M, Burra P, Torrani Cerenzia M, Barsic B, Calbo E, Maraolo AE, Petrosillo N, Galan-Ladero MA, D'Offizi G, Bar Sinai N, Rodríguez-Baño J, Verucchi G, Bernardi M, Viale P; ESGBIS/BICHROME Study Group.

Clin Microbiol Infect. 2018 May;24(5):546.e1-546.e8. doi: 10.1016/j.cmi.2017.08.001. Epub 2017 Aug 14.

17.

Characterization of Naturally Occurring NS5A and NS5B Polymorphisms in Patients Infected with HCV Genotype 3a Treated with Direct-Acting Antiviral Agents.

Bartolini B, Giombini E, Taibi C, Lionetti R, Montalbano M, Visco-Comandini U, D'Offizi G, Capobianchi MR, McPhee F, Garbuglia AR.

Viruses. 2017 Aug 7;9(8). pii: E212. doi: 10.3390/v9080212.

18.

Dendritic cells activation is associated with sustained virological response to telaprevir treatment of HCV-infected patients.

Sacchi A, Tumino N, Turchi F, Refolo G, Fimia G, Ciccosanti F, Montalbano M, Lionetti R, Taibi C, D'Offizi G, Casetti R, Bordoni V, Cimini E, Martini F, Agrati C.

Clin Immunol. 2017 Oct;183:82-90. doi: 10.1016/j.clim.2017.07.017. Epub 2017 Jul 20.

PMID:
28736275
19.

Efficacy of sofosbuvir and ledipasvir in an HCV+ gastro-resected patient.

Taibi C, Tempestilli M, D'Avolio A, Garbuglia AR, De Nicolò A, Montalbano M, D'Offizi G.

J Clin Pharm Ther. 2017 Oct;42(5):621-623. doi: 10.1111/jcpt.12546. Epub 2017 May 4.

PMID:
28474408
20.

Evolutionary trends of resistance mutational patterns of HBV reverse transcriptase over years (2002-2012) of different treatment regimens: The legacy of lamivudine/adefovir combination treatment.

Vincenti D, Piselli P, Solmone M, D'Offizi G, Capobianchi MR, Menzo S.

Antiviral Res. 2017 Jul;143:62-68. doi: 10.1016/j.antiviral.2017.03.008. Epub 2017 Mar 18.

PMID:
28322924
21.

Effectiveness of Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir in Hemodialysis Patients With Hepatitis C Virus Infection and Advanced Liver Fibrosis: Case Reports.

Ponziani FR, Siciliano M, Lionetti R, Pasquazzi C, Gianserra L, D'Offizi G, Gasbarrini A, Pompili M.

Am J Kidney Dis. 2017 Aug;70(2):297-300. doi: 10.1053/j.ajkd.2017.01.037. Epub 2017 Mar 1.

PMID:
28258770
22.

Clinical and virological predictors of sustained response with an interferon-based simeprevir regimen for patients with chronic genotype 1 hepatitis C virus infection.

D'Offizi G, Cammà C, Taibi C, Schlag M, Weber K, Palma M, DeMasi R, Janssen K, Witek J, Lionetti R.

New Microbiol. 2017 Jan;40(1):19-26. Epub 2017 Jan 9.

23.

A 15-year experience of two hundred and twenty five consecutive right hepatectomies.

Levi Sandri GB, Colasanti M, Vennarecci G, Santoro R, Lepiane P, Mascianà G, de Werra E, Meniconi RL, Campanelli A, Scotti A, Burocchi M, Di Castro A, D'Offizi G, Antonini M, Busi Rizzi E, Ialongo P, Garufi C, Ettorre GM.

Dig Liver Dis. 2017 Jan;49(1):50-56. doi: 10.1016/j.dld.2016.09.014. Epub 2016 Sep 28.

PMID:
27720699
24.

Ultrasensitive HCV RNA Quantification in Antiviral Triple Therapy: New Insight on Viral Clearance Dynamics and Treatment Outcome Predictors.

Garbuglia AR, Visco-Comandini U, Lionetti R, Lapa D, Castiglione F, D'Offizi G, Taibi C, Montalbano M, Capobianchi MR, Paci P.

PLoS One. 2016 Aug 25;11(8):e0158989. doi: 10.1371/journal.pone.0158989. eCollection 2016.

25.

Yttrium-90 Radioembolization for Hepatocellular Carcinoma Prior to Liver Transplantation.

Ettorre GM, Levi Sandri GB, Laurenzi A, Colasanti M, Meniconi RL, Lionetti R, Santoro R, Lepiane P, Sciuto R, Pizzi G, Cianni R, Golfieri R, D'Offizi G, Pellicelli AM, Antonini M, Vennarecci G.

World J Surg. 2017 Jan;41(1):241-249. doi: 10.1007/s00268-016-3682-z.

PMID:
27495316
26.

Virological response and resistance profile in HIV-1-infected patients starting darunavir-containing regimens.

Armenia D, Di Carlo D, Maffongelli G, Borghi V, Alteri C, Forbici F, Bertoli A, Gori C, Giuliani M, Nicastri E, Zaccarelli M, Pinnetti C, Cicalini S, D'Offizi G, Ceccherini-Silberstein F, Mussini C, Antinori A, Andreoni M, Perno CF, Santoro MM.

HIV Med. 2017 Jan;18(1):21-32. doi: 10.1111/hiv.12388. Epub 2016 Jun 28.

27.

ALPPS for primary and secondary liver tumors.

Vennarecci G, Grazi GL, Sperduti I, Busi Rizzi E, Felli E, Antonini M, D'Offizi G, Ettorre GM.

Int J Surg. 2016 Jun;30:38-44. doi: 10.1016/j.ijsu.2016.04.031. Epub 2016 Apr 22.

28.

Extracellular Matrix Molecular Remodeling in Human Liver Fibrosis Evolution.

Baiocchini A, Montaldo C, Conigliaro A, Grimaldi A, Correani V, Mura F, Ciccosanti F, Rotiroti N, Brenna A, Montalbano M, D'Offizi G, Capobianchi MR, Alessandro R, Piacentini M, Schininà ME, Maras B, Del Nonno F, Tripodi M, Mancone C.

PLoS One. 2016 Mar 21;11(3):e0151736. doi: 10.1371/journal.pone.0151736. eCollection 2016.

29.

Repeated Cycles of Recombinant Human Interleukin 7 in HIV-Infected Patients With Low CD4 T-Cell Reconstitution on Antiretroviral Therapy: Results of 2 Phase II Multicenter Studies.

Thiébaut R, Jarne A, Routy JP, Sereti I, Fischl M, Ive P, Speck RF, D'Offizi G, Casari S, Commenges D, Foulkes S, Natarajan V, Croughs T, Delfraissy JF, Tambussi G, Levy Y, Lederman MM.

Clin Infect Dis. 2016 May 1;62(9):1178-1185. doi: 10.1093/cid/ciw065. Epub 2016 Feb 7.

30.

Laparoscopic liver resection for hepatocellular carcinoma in cirrhotic patients: single center experience of 90 cases.

Ettorre GM, Levi Sandri GB, Santoro R, Vennarecci G, Lepiane P, Colasanti M, Felli E, de Werra E, Colace L, D'Offizi G, Montalbano M, Visco U, Maritti M, Antonini M, Santoro E.

Hepatobiliary Surg Nutr. 2015 Oct;4(5):320-4. doi: 10.3978/j.issn.2304-3881.2015.06.13.

31.

HCV NS3 quasispecies in liver and plasma and dynamics of telaprevir-resistant variants in breakthrough patients assessed by UDPS: A case study.

Bartolini B, Selleri M, Garbuglia AR, Giombini E, Taibi C, Lionetti R, D'Offizi G, Capobianchi MR.

J Clin Virol. 2015 Nov;72:60-5. doi: 10.1016/j.jcv.2015.07.310. Epub 2015 Jul 30.

PMID:
26418073
32.

Endocarditis and meningitis associated to nape piercing in a young female: a case report.

Mariano A, Pisapia R, Abdeddaim A, Taibi C, Rianda A, Vincenzi L, D'Offizi G.

Infez Med. 2015 Sep;23(3):275-9.

33.

The clinical significance of HCV core antigen detection during Telaprevir/Peg-Interferon/Ribavirin therapy in patients with HCV 1 genotype infection.

Garbuglia AR, Lionetti R, Lapa D, Taibi C, Visco-Comandini U, Montalbano M, D'Offizi G, Castiglione F, Capobianchi MR, Paci P.

J Clin Virol. 2015 Aug;69:68-73. doi: 10.1016/j.jcv.2015.06.002. Epub 2015 Jun 5.

PMID:
26209382
34.

Primary and Chronic HIV Infection Differently Modulates Mucosal Vδ1 and Vδ2 T-Cells Differentiation Profile and Effector Functions.

Cimini E, Agrati C, D'Offizi G, Vlassi C, Casetti R, Sacchi A, Lionetti R, Bordoni V, Tumino N, Scognamiglio P, Martini F.

PLoS One. 2015 Jun 18;10(6):e0129771. doi: 10.1371/journal.pone.0129771. eCollection 2015.

35.

Dynamics of HCV genotype 4 resistance-associated variants during virologic escape with pIFN/RBV+daclatasvir: a case study using ultra deep pyrosequencing.

Bartolini B, Lionetti R, Giombini E, Sias C, Taibi C, Montalbano M, D'Offizi G, McPhee F, Hughes EA, Zhou N, Ippolito G, Garbuglia AR, Capobianchi MR.

J Clin Virol. 2015 May;66:38-43. doi: 10.1016/j.jcv.2015.02.001. Epub 2015 Feb 16. Erratum in: J Clin Virol. 2015 Aug;69:252. Gianpiero, D'Offizi [corrected to D'Offizi, Gianpiero].

PMID:
25866334
36.

HIV-1 integrase genotyping is reliable and reproducible for routine clinical detection of integrase resistance mutations even in patients with low-level viraemia.

Armenia D, Fabeni L, Alteri C, Di Pinto D, Di Carlo D, Bertoli A, Gori C, Carta S, Fedele V, Forbici F, D'Arrigo R, Svicher V, Berno G, Pizzi D, Nicastri E, Sarmati L, Pinnetti C, Ammassari A, D'Offizi G, Latini A, Andreoni M, Antinori A, Ceccherini-Silberstein F, Perno CF, Santoro MM.

J Antimicrob Chemother. 2015;70(6):1865-73. doi: 10.1093/jac/dkv029. Epub 2015 Feb 23.

37.

Rapid and preemptive evaluation of individual anti-hepatitis C virus treatment outcome capability by a short-term autologous liver tissue culture system.

Cimini E, Bordoni V, Lalle E, Montalbano M, Visco-Comandini U, Taibi C, D'Offizi G, Lionetti R, Scognamiglio P, Capobianchi MR, Martini F, Agrati C.

New Microbiol. 2014 Jul;37(3):363-7. Epub 2014 Jul 1.

38.

Recommendations for the management of acute hepatitis B: position paper of the Italian Society for the Study of Infectious and Tropical Diseases (SIMIT).

Bruno R, Carosi G, Coppola N, Gaeta GB, Puoti M, Santantonio T, Taliani G, Armignacco O, Sagnelli E, Andreoni M, Angarano G, Di Perri G, D'Offizi G, Galli M, Rizzardini G; Italian Society for the Study of Infectious and Tropical Diseases.

Infection. 2014 Oct;42(5):811-5. doi: 10.1007/s15010-014-0642-0. Epub 2014 Jul 6. Review.

PMID:
24997980
39.

Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: potent antiviral activity but no clinical benefit if treatment is given late.

Pellicelli AM, Montalbano M, Lionetti R, Durand C, Ferenci P, D'Offizi G, Knop V, Telese A, Lenci I, Andreoli A, Zeuzem S, Angelico M.

Dig Liver Dis. 2014 Oct;46(10):923-7. doi: 10.1016/j.dld.2014.06.004. Epub 2014 Jul 3.

PMID:
24997638
40.

Autophagy plays an important role in the containment of HIV-1 in nonprogressor-infected patients.

Nardacci R, Amendola A, Ciccosanti F, Corazzari M, Esposito V, Vlassi C, Taibi C, Fimia GM, Del Nonno F, Ippolito G, D'Offizi G, Piacentini M.

Autophagy. 2014 Jul;10(7):1167-78. doi: 10.4161/auto.28678. Epub 2014 Apr 29.

41.

The ALPPS procedure for hepatocellular carcinoma.

Vennarecci G, Laurenzi A, Levi Sandri GB, Busi Rizzi E, Cristofaro M, Montalbano M, Piselli P, Andreoli A, D'Offizi G, Ettorre GM.

Eur J Surg Oncol. 2014 Aug;40(8):982-8. doi: 10.1016/j.ejso.2014.04.002. Epub 2014 Apr 13.

PMID:
24767805
42.

Laparoscopic liver resections in normal and cirrhotic livers: a retrospective analysis in a tertiary hepato-biliary unit.

Ettorre GM, Laurenzi A, Lionetti R, Santoro R, Lepiane P, Colasanti M, Colace L, Piselli P, Puoti C, D'Offizi G, Antonini M, Vennarecci G.

Dig Liver Dis. 2014 Apr;46(4):353-7. doi: 10.1016/j.dld.2013.12.002. Epub 2014 Jan 13.

PMID:
24433996
43.

Reliability and clinical relevance of the HIV-1 drug resistance test in patients with low viremia levels.

Santoro MM, Fabeni L, Armenia D, Alteri C, Di Pinto D, Forbici F, Bertoli A, Di Carlo D, Gori C, Carta S, Fedele V, D'Arrigo R, Berno G, Ammassari A, Pinnetti C, Nicastri E, Latini A, Tommasi C, Boumis E, Petrosillo N, D'Offizi G, Andreoni M, Ceccherini-Silberstein F, Antinori A, Perno CF.

Clin Infect Dis. 2014 Apr;58(8):1156-64. doi: 10.1093/cid/ciu020. Epub 2014 Jan 14.

44.

Increased plasma concentration of ribavirin as a result of renal dysfunction in hepatitis C virus patients treated with telaprevir.

Tempestilli M, Lionetti R, D'Offizi G, Montalbano M, Giaffreda A, Fazio S, Pucillo LP.

Hepatology. 2014 Sep;60(3):1109-10. doi: 10.1002/hep.26978. Epub 2014 Jul 28. No abstract available.

PMID:
24375509
45.

Quasispecies tropism and compartmentalization in gut and peripheral blood during early and chronic phases of HIV-1 infection: possible correlation with immune activation markers.

Rozera G, Abbate I, Vlassi C, Giombini E, Lionetti R, Selleri M, Zaccaro P, Bartolini B, Corpolongo A, D'Offizi G, Baiocchini A, Del Nonno F, Ippolito G, Capobianchi MR.

Clin Microbiol Infect. 2014 Mar;20(3):O157-66. doi: 10.1111/1469-0691.12367. Epub 2013 Oct 18.

46.

Determination of telaprevir in plasma of HCV-infected patients by HPLC-UV.

Tempestilli M, Milano E, D'Offizi G, Montalbano M, D'Avolio A, Gasperi T, Narciso P, Ascenzi P, Pucillo LP.

IUBMB Life. 2013 Sep;65(9):800-5. doi: 10.1002/iub.1197. Epub 2013 Jul 29.

47.

Acute hepatitis associated with clopidogrel: a case report and review of the literature.

Pisapia R, Abdeddaim A, Mariano A, Rianda A, Vincenzi L, Taibi C, Baiocchini A, Del Nonno F, DʼOffizi G.

Am J Ther. 2015 Jan-Feb;22(1):e8-e13. doi: 10.1097/MJT.0b013e318293b0d6. Review.

PMID:
23846525
48.

In HIV/HCV coinfected patients dendritic cell activation state is not associated with IL28B genotype.

Sacchi A, Lapa D, Garbuglia AR, Taibi C, Tumino N, D'Offizi G, Martini F.

J Infect Dis. 2013 Jul 15;208(2):364-5. doi: 10.1093/infdis/jit161. Epub 2013 Apr 9. No abstract available.

PMID:
23570849
49.

In vivo interferon-alpha/ribavirin treatment modulates Vγ9Vδ2 T-cell function during chronic HCV infection.

Cimini E, Bonnafous C, Sicard H, Vlassi C, D'Offizi G, Capobianchi MR, Martini F, Agrati C.

J Interferon Cytokine Res. 2013 Mar;33(3):136-41. doi: 10.1089/jir.2012.0050. Epub 2013 Jan 11.

PMID:
23308376
50.

Ultra-deep sequencing reveals hidden HIV-1 minority lineages and shifts of viral population between the main cellular reservoirs of the infection after therapy interruption.

Rozera G, Abbate I, Ciccozzi M, Lo Presti A, Bruselles A, Vlassi C, D'Offizi G, Narciso P, Giombini E, Bartolini B, Ippolito G, Capobianchi MR.

J Med Virol. 2012 Jun;84(6):839-44. doi: 10.1002/jmv.23292.

PMID:
22996031

Supplemental Content

Loading ...
Support Center